XTNT Stock - Xtant Medical Holdings, Inc.
Unlock GoAI Insights for XTNT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $117.27M | $91.30M | $57.97M | $55.26M | $53.34M |
| Gross Profit | $68.22M | $55.47M | $32.14M | $32.49M | $34.39M |
| Gross Margin | 58.2% | 60.8% | 55.4% | 58.8% | 64.5% |
| Operating Income | $-12,074,000 | $-10,158,000 | $-6,755,000 | $-3,854,000 | $-751,000 |
| Net Income | $-16,449,000 | $660,000 | $-8,485,000 | $-4,849,000 | $-7,023,000 |
| Net Margin | -14.0% | 0.7% | -14.6% | -8.8% | -13.2% |
| EPS | $-0.12 | $0.01 | $-0.09 | $-0.06 | $-0.25 |
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; OsteoFactor, which contains various proteins and peptides that support bone formation and remodeling; OsteoWrap; and OsteoVive Plus, a growth factor enriched cellular bone matrix. The company also provides 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company offers Certex spinal fixation, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, Xpress minimally invasive pedicle screw, and Fortex Pedicle screw systems. Additionally, it provides Calix for cervical and thoracolumbar applications, Axle-X interspinous fusion system, Irix-C cervical integrated fusion system, and Irix-A Lumbar integrated fusion system. The company was formerly known as Bacterin International Holdings, Inc. and changed its name to Xtant Medical Holdings, Inc. in July 2015. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 5th 2023 | BTIG Research | Initiation | Buy | $2 |
Earnings History & Surprises
XTNTEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 4, 2026 | — | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.01 | $0.01 | +290.5% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-0.01 | $0.02 | +300.0% | ✓ BEAT |
Q2 2025 | May 12, 2025 | $-0.01 | $0.00 | +104.0% | ✓ BEAT |
Q1 2025 | Mar 6, 2025 | $-0.01 | $-0.02 | -100.0% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.03 | $-0.04 | -60.0% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.02 | $-0.03 | -50.0% | ✗ MISS |
Q2 2024 | May 15, 2024 | $-0.01 | $-0.03 | -100.0% | ✗ MISS |
Q2 2024 | Apr 1, 2024 | $-0.03 | $-0.03 | -20.0% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $0.01 | $0.07 | +449.9% | ✓ BEAT |
Q3 2023 | Aug 1, 2023 | $-0.02 | $-0.02 | 0.0% | = MET |
Q2 2023 | May 4, 2023 | $-0.01 | $-0.02 | -33.3% | ✗ MISS |
Q1 2023 | Mar 7, 2023 | — | $-0.02 | — | — |
Q4 2022 | Nov 3, 2022 | — | $-0.03 | — | — |
Q3 2022 | Aug 4, 2022 | — | $-0.02 | — | — |
Q2 2022 | May 5, 2022 | — | $-0.03 | — | — |
Q1 2022 | Mar 8, 2022 | — | $-0.03 | — | — |
Q4 2021 | Nov 12, 2021 | — | $-0.02 | — | — |
Q3 2021 | Aug 5, 2021 | — | $-0.01 | — | — |
Latest News
Xtant Medical Announces Commercial Launch Of nanOss Strata Synthetic Bone Graft
📈 PositiveBTIG Maintains Buy on Xtant Medical Hldgs, Lowers Price Target to $1.5
➖ NeutralXtant Medical Hldgs Affirms FY2025 Sales Guidance of $131.000M-$135.000M vs $129.950M Est
📈 PositiveXtant Medical Holdings Reiterates FY25 Guidance $131M-$135M
➖ NeutralXtant Medical Hldgs Q3 EPS $0.01 Beats $(0.01) Estimate, Sales $33.300M Beat $32.700M Estimate
📈 PositiveFrequently Asked Questions about XTNT
What is XTNT's current stock price?
What is the analyst price target for XTNT?
What sector is Xtant Medical Holdings, Inc. in?
What is XTNT's market cap?
Does XTNT pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to XTNT for comparison